SMFM Conference and Publications Highlight the Challenges and Complexities of Diagnosing and Managing Preeclampsia SAN DIEGO, Feb. 12, 2021 (GLOBE NEWSWIRE) -- Progenity, Inc. (Nasdaq: PROG), a biotechnology company with an established track record of success in developing and commercializing molecular testing...

Research on Underlying Mechanisms of Pregnancy Complications and Medical Interventions Using Sera’s Proteomic Technology to be Presented at the Society for Maternal-Fetal Medicine’s 37th Annual Pregnancy Meeting SALT LAKE CITY, Jan. 23, 2017 (GLOBE NEWSWIRE) -- Sera Prognostics, Inc., a women’s healthcare company, today announced the presentation of ongoing research evaluating the underlying mechanisms of...

Positive Clinical Validation Data for PreTRM® Test Presented at the Society for Maternal-Fetal Medicine’s 36th Annual Pregnancy Meeting SALT LAKE CITY, Feb. 04, 2016 (GLOBE NEWSWIRE) -- Sera Prognostics, Inc., a women’s healthcare company, today announced that results from the 5,501-patient Proteomic Assessment of Preterm Risk...